Changes in the expression of voltage-gated K+ currents during development of human megakaryocytic cells

AbstractWe distinguished four distinct groups of megakaryocytic cells on the basis of their voltage-gated membrane currents. One group of 32 cells (15%), exhibited an inward rectifying current and had a diameter of 12±3.5 μm (mean±S.D.). A large group of 85 cells (39%) exhibited only a `leakage-like' current and had a diameter of 15.8±3.7 μm. The other two groups of cells exhibited voltage-gated outward currents. One group consisted of 43 `I-type' cells (19%), with a diameter of 22.3±3.4 μm, for which the maximal outward current occurred for a voltage step from −60 to either 0 or +20 mV. For the last group of 60 `M-type' cells (27%), which had a diameter of 26.7±2.9 μm, the maximal outward current occurred for a voltage step from −60 to +80 mV, the largest voltage step used. The currents recorded in this study, from megakaryocytes having `leakage-like' currents and `I-type' currents, were indistinguishable from the voltage-gated currents of the megakaryocytes from myelogenous leukemia patients, in which voltage-gated currents were suppressed (Kapural, L., O'Rourke, F., Feinstein, M.B. and Fein, A. (1995) Blood 86, 1043), suggesting that the megakaryocytes from the myelogenous leukemia patients are a dedifferentiated or less mature form of megakaryocyte

Provocative discography and minimally invasive procedures for the treatment of discogenic pain

Diagnosis and treatment of lumbar discogenic pain remains a challenge. It may account for 1/3 of patients with lower back pain. The mechanism of discogenic pain remains unclear, clinical presentation can vary and the MRI may only suggest the presence of internal disc disruption. Provocative discography can provide unique information about the morphology of the disc and remains the only diagnostic test that can relate the changes observed on imaging tests and the patient’s pain. Minimally invasive treatments like intradiscal biacuplasty or intradiscal electrothermal therapy are likely better alternatives to the currently available surgical options. They are cost effective and may cause fewer side effects. However, the value of most of these therapies has yet to be established. More basic science and clinical studies are needed to prove the clinical efficacy of such minimal invasive treatments. One thing that is clear, however, is that the careful patient selection, based on the present data, significantly improves successes of these procedures

One Year Follow-up of a Randomized, Double-Blind, Placebo-Controlled Trial of Percutaneous Peripheral Nerve Stimulation for Chronic Neuropathic Pain Following Amputation

Abstract INTRODUCTION Over 85% of patients experience residual limb (RLP) and/or phantom limb (PLP) pain following amputation. Peripheral nerve stimulation (PNS) is a non-opioid approach to relieve postamputation neuropathic pain. A recent multicenter, randomized, double-blind, placebo-controlled study using a novel percutaneous PNS system demonstrated clinically and statistically significant improvements in pain and pain interference with PNS compared to placebo (Gilmore et al, 2019). This work presents prospective 1-yr follow-up to assess durability of pain relief and functional improvements. METHODS Over 85% of patients experience residual limb (RLP) and/or phantom limb (PLP) pain following amputation. Peripheral nerve stimulation (PNS) is a non-opioid approach to relieve post-amputation neuropathic pain. A recent multicenter, randomized, double-blind, placebo-controlled study using a novel percutaneous PNS system demonstrated clinically and statistically significant improvements in pain and pain interference with PNS compared to placebo (Gilmore et al, 2019). This work presents prospective one-year follow-up to assess durability of pain relief and functional improvements. RESULTS A significantly greater proportion of subjects who completed the 12-mo visit reported = 50% pain relief on the BPI-SF (5/8, 63%; average pain relief = 73% among responders) compared to the placebo group at the time of crossover (0/14, 0%, P = .003; average pain relief = 23%). A majority of subjects also reported = 50% reductions in pain interference at 12 mo (5/8, 63%). Two of 13 (15%) subjects in the placebo group reported sustained improvements in pain interference (P = .06). Average reduction in pain interference among responders in the PNS group was 87%. CONCLUSION This work suggests that PNS delivered over 60 d may provide clinically significant and enduring pain relief, enabling improved function and potentially reducing the need for a permanently implanted system

Finding Folk: Contemporary Craft Regionalism

This thesis considers place and belonging and explores craft as a method of discovering community. I recently moved my furniture practice from Toronto to Prince Edward County, an agricultural region in rural Ontario. This relocation inspired my research; Prince Edward County was the setting of this work and the community in which I attempted to form connections through my practice. The principles of architectural theory Critical Regionalism were applied as a framework for the design of new regional furniture. The concept of becoming through making is explored throughout this research and refers to both a maker’s acquisition of embodied and material knowledge, and to becoming part of a community. The paper documents the process of developing a body of work informed by Critical Regionalism, taking the form of wooden seats, and an engagement with community members through various craft-based projects, ranging from bending a metal basket to knitting furniture

Clinical applications of neurostimulation: forty years later

Abstract: With the recent technological advances, neurostimulation has provided new hope for millions of patients with debilitating chronic pain conditions that respond poorly to other therapies. Outcome research demonstrated that patients with failed back surgery syndrome and complex regional pain syndromes benefit significantly from neurostimulation in pain reduction, functional capacity, and quality of life. Increasing clinical evidence supports the use of neurostimulation in post-herpetic neuralgia, peripheral neuropathy, occipital neuralgia, and other neuropathic pain conditions. Strong clinical evidences indicate that neurostimulation offers less invasive and more effective therapies for many patients with ischemic pain caused by cardiovascular and peripheral vascular diseases. A growing body of literature supports neurostimulation for visceral pain in general and interstitial cystitis in particular. As a basic principle, patient selection for the appropriate neurostimulation modalities is essential for safe, efficacious, and costeffective applications of this therapy. Research with more vigorous designs is needed to establish evidence-based applications of neuromodulation therapy in emerging indications of pain management

Validation of standard operating procedures in a multicenter retrospective study to identify-omics biomarkers for chronic low back pain

Chronic low back pain (CLBP) is one of the most common medical conditions, ranking as the greatest contributor to global disability and accounting for huge societal costs based on the Global Burden of Disease 2010 study. Large genetic and -omics studies provide a promising avenue for the screening, development and validation of biomarkers useful for personalized diagnosis and treatment (precision medicine). Multicentre studies are needed for such an effort, and a standardized and homogeneous approach is vital for recruitment of large numbers of participants among different centres (clinical and laboratories) to obtain robust and reproducible results. To date, no validated standard operating procedures (SOPs) for genetic/-omics studies in chronic pain have been developed. In this study, we validated an SOP model that will be used in the multicentre (5 centres) retrospective “PainOmics” study, funded by the European Community in the 7th Framework Programme, which aims to develop new biomarkers for CLBP through three different -omics approaches: genomics, glycomics and activomics. The SOPs describe the specific procedures for (1) blood collection, (2) sample processing and storage, (3) shipping details and (4) cross-check testing and validation before assays that all the centres involved in the study have to follow. Multivariate analysis revealed the absolute specificity and homogeneity of the samples collected by the five centres for all genetics, glycomics and activomics analyses. The SOPs used in our multicenter study have been validated. Hence, they could represent an innovative tool for the correct management and collection of reliable samples in other large-omics-based multicenter studies

Cost-effectiveness of 10-kHz Spinal Cord Stimulation Therapy Compared With Conventional Medical Management Over the First 12 Months of Therapy for Patients With Nonsurgical Back Pain: Randomized Controlled Trial

Objective: This analysis evaluated if spinal cord stimulation (SCS) at 10 kHz plus conventional medical management (CMM) is cost-effective compared with CMM alone for the treatment of nonsurgical refractory back pain (NSRBP). Methods: NSRBP subjects were randomized 1:1 into the 10-kHz SCS (n = 83) or CMM (n = 76) group. Outcomes assessed at 6 months included EQ-5D 5-level (EQ-5D-5L), medication usage, and healthcare utilization (HCU). There was an optional crossover at 6 months and follow-up to 12 months. The incremental cost-effectiveness ratio (ICER) was calculated with cost including all HCU and medications except for the initial device and implant procedure, and cost-effectiveness was analyzed based on a willingness-to-pay threshold of \u3c $50,000 per quality-adjusted life-year. Results: Treatment with 10-kHz SCS resulted in a significant improvement in quality of life (QOL) over CMM (EQ-5D-5L index score change of 0.201 vs -0.042, p \u3c 0.001) at a lower cost, based on reduced frequency of HCU resulting in an ICER of -$4964 at 12 months. The ICER was -$8620 comparing the 6 months on CMM with postcrossover on 10-kHz SCS. Conclusions: Treatment with 10-kHz SCS provides higher QOL at a lower average cost per patient compared with CMM. Assuming an average reimbursement for device and procedure, 10-kHz SCS therapy is predicted to be cost-effective for the treatment of NSRBP compared with CMM within 2.1 years

Omics\u27 biomarkers associated with chronic low back pain: Protocol of a retrospective longitudinal study

Introduction Chronic low back pain (CLBP) produces considerable direct costs as well as indirect burdens for society, industry and health systems. CLBP is characterised by heterogeneity, inclusion of several pain syndromes, different underlying molecular pathologies and interaction with psychosocial factors that leads to a range of clinical manifestations. There is still much to understand in the underlying pathological processes and the non-psychosocial factors which account for differences in outcomes. Biomarkers that may be objectively used for diagnosis and personalised, targeted and cost-effective treatment are still lacking. Therefore, any data that may be obtained at the-omics\u27 level (glycomics, Activomics and genome-wide association studies-GWAS) may be helpful to use as dynamic biomarkers for elucidating CLBP pathogenesis and may ultimately provide prognostic information too. By means of a retrospective, observational, case-cohort, multicentre study, we aim to investigate new promising biomarkers potentially able to solve some of the issues related to CLBP. Methods and analysis The study follows a two-phase, 1:2 case-control model. A total of 12 000 individuals (4000 cases and 8000 controls) will be enrolled; clinical data will be registered, with particular attention to pain characteristics and outcomes of pain treatments. Blood samples will be collected to perform-omics studies. The primary objective is to recognise genetic variants associated with CLBP; secondary objectives are to study glycomics and Activomics profiles associated with CLBP. Ethics and dissemination The study is part of the PainOMICS project funded by European Community in the Seventh Framework Programme. The study has been approved from competent ethical bodies and copies of approvals were provided to the European Commission before starting the study. Results of the study will be reviewed by the Scientific Board and Ethical Committee of the PainOMICS Consortium. The scientific results will be disseminated through peer-reviewed journals. Trial registration number NCT02037789; Pre-results